Structure Therapeutics Inc.
GPCR
Positions held
Your positionsGPCR isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Structure Therapeutics Inc. operates in the biotechnology sector, which is known for its potential to innovate and develop groundbreaking therapies, attracting significant investor interest.
- The company's market cap stands at approximately $1.96 billion, indicating a substantial valuation in the biotech space.
- Despite current challenges, the target mean price for GPCR is $105.78, suggesting potential upside for investors.
- The company has reported negative net income for multiple quarters, with a net loss of $106.16 million in Q2 2026.
- Structure Therapeutics has not generated any revenue in the last several quarters, maintaining a revenue of $0.0.
- The stock has a strong sell signal with a score of -24.00, indicating significant bearish sentiment among analysts.
Fundamentals
| Market cap | $1.83B | Enterprise value | $494.09M | Trailing P/E | — | Forward P/E | -12.15 |
| PEG | — | Price / book | 1.35 | Beta | -1.37 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -20.2% | ROA | -14.9% | Debt / equity | 0.00 |
| Current ratio | 20.75 | Free cash flow | -$119.06M | Analyst recommendation | strong_buy | Mean target | $105.78 |
| 52w high | $94.90 | 52w low | $25.09 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$106M | -$76.0M | $33.0M | -$65.7M | -$61.7M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$119M | -$89.4M | $13.7M | -$73.8M | -$70.5M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$141M | -$123M | -$89.6M | -$51.3M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$187M | -$158M | -$103M | -$52.6M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?
2026-09-30 · Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
2026-09-23 · Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
2026-09-22 · Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results
2026-09-22 · Structure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In Focus
2026-09-22 · VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’
2026-09-17 · LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?
2026-09-17 · Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?
2026-09-14 · Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
2026-09-10 · Structure Therapeutics (GPCR): Will Repeat Dosing Confirm Its 3.3% Weight-Loss Signal?
2026-09-08 · Structure Therapeutics Reports Up to 16.2% Weight Loss in Aleniglipron Trial
2026-09-08 · Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study
Price (daily)
Full chart · RSI · MACD · patterns